key: cord-0874366-cio6hf6u
authors: Levitus, Matthew; Shainker, Scott A.; Colvin, Mai
title: COVID-19 in the Critically Ill Pregnant Patient
date: 2022-01-10
journal: Crit Care Clin
DOI: 10.1016/j.ccc.2022.01.003
sha: 928586367380fedcf2d893e6077ac17add5a2a7b
doc_id: 874366
cord_uid: cio6hf6u

Pregnant women are at increased risk for severe coronavirus disease 2019 (COVID-19) and COVID-19 related complications. Their increased risk in conjuncture with the normal physiologic changes of pregnancy poses unique challenges for the management of the critically ill pregnant patient. This paper will review the initial management of pregnant patients who develop acute hypoxic respiratory failure and subsequent treatment of those that deteriorate to acute respiratory distress syndrome and require advanced therapies. Moreover, fetal monitoring and timing of delivery will be reviewed.

Information related to coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in pregnant patients is limited and continues to emerge. Even less is known about the critically ill pregnant patient requiring advanced respiratory support or those that progress to the development of acute respiratory distress syndrome (ARDS). Pregnant patients are more likely to have severe COVID-19 illnesses compared to nonpregnant patients. A large study from the Centers of Disease Control and Prevention (CDC) which reviewed reports of more than 1.3 million women of reproductive age with a laboratory confirmed SARS-CoV-2 infection showed that among women with COVID-19, pregnant patients were at significantly increased risk for intensive care unit (ICU) admission, mechanical ventilation, receipt of extracorporeal membrane oxygenation (ECMO), and death. 1 Furthermore, they are at greater risk for adverse pregnancy related outcomes, driven by an increased risk of iatrogenic prematurity. [2] [3] [4] Factors such as age above 25 years, obesity, chronic hypertension, chronic lung disease, gestational diabetes, and pre-eclampsia further increase risks of serious complications. 1, [5] [6] [7] The physiologic changes of pregnancy necessitate special considerations when attempting to optimize management. Pregnancy results in hyperemia of the upper airway, increased oxygen consumption, reduction in chest wall compliance, and decreased functional residual capacity, all of which can exacerbate respiratory distress. [8] [9] [10] . Moreover, pregnancy is a hypercoagulable state, leads to modifications of the immune system, and produces a state of increased cardiac output. 9 Standard COVID-19 management is also affected by presence of the fetus, as maternal hypoxemia and hypercapnia can be harmful. The utility of treatments and interventions must therefore be weighed against their safety and risks to the developing fetus.

Given their increased risk of severe COVID-19, unique physiology, and fetal considerations, the clinician requires a detailed understanding of the management of critically ill pregnant patients. This paper will provide a detailed review of the management and care for the critically ill pregnant patient with severe COVID-19 pneumonia.

If pregnant women are suspected or proven to be infected with COVID-19, especially in the presence of high-risk factors, prompt clinical evaluation, early identification of severe symptoms, and appropriate triage is necessary to improve their outcomes. The International Society of Infectious Disease in Obstetrics and Gynecology (ISIDOG) guidelines suggest that ICU admission should be considered for the following patients: (A) "Pregnant patients with severe disease: respiratory rate ≥ 30/min, resting oxygen saturation SaO2 < 94%, arterial blood oxygen partial pressure (PaO2)/oxygen concentration (FiO2) (P/F) ≤ 300 mmHg." (B) "Pregnant patients with oxygen requirement and comorbidities." (C) "Pregnant patients with critical disease: shock with organ failure, respiratory failure requiring mechanical ventilation or refractory hypoxemia requiring ECMO." 11 In severe/critical cases or in cases where specialized treatment is required, pregnant patients should be referred to a tertiary center immediately.

Overall, there is limited data regarding the management of the critically ill pregnant patient with COVID-19 as many studies excluded pregnant patients or had limited participants. After identification of critical illness, care should focus on specific treatments for the range of the disease caused by COVID-19 including those with acute respiratory failure to those who develop severe J o u r n a l P r e -p r o o f ARDS. Furthermore, there should be a focus on the monitoring of the fetus and discussion of treatment decisions regarding a viable vs non-viable fetus. (Figure 1 )

It is well establish that antenatal glucocorticoids in patients at high risk of preterm delivery within 7 days improves neonatal outcomes. 12 Treatment typically consists of either two 12 mg doses of betamethasone given intramuscularly (IM) 24 hours apart or four 6 mg doses of dexamethasone administered IM every 12 hours. 12, 13 Prolonged use or multiple courses of steroids that readily cross the placenta is controversial as prior studies have shown potential adverse fetal effects such as unfavorable neurologic outcomes, small head circumferences, fetal growth restriction, and increased risk of neonatal hypoglycemia. 12, 14, 15 The RECOVERY trial showed that oral or intravenous (IV) dexamethasone at a dose of 6 mg once daily for up to 10 days reduces mortality associated with COVID-19 among patients who required supplemental oxygen or mechanical ventilation compared to those who received standard of care. 16 Pregnant patients were not excluded from the trial, but the trial included only six pregnant patients and the protocol was modified to treatment with oral prednisolone 40 mg daily or IV hydrocortisone 80 mg twice daily.

Evidence on the choice and duration of corticosteroid treatment among pregnant patients with COVID-19 is limited and a definitive consensus is lacking. (Table-1 15 This is suggested due to the potential harm from additional dexamethasone exposure to the fetus. 15 In contrast, the Society of Maternal Fetal Medicine (SMFM) recommends the use of dexamethasone in a similar manner to that studied in the RECOVERY trial. 18 The above recommendations are modified for patients that meet criteria for steroids for fetal lung maturity by treatment with dexamethasone 6mg IM every 12 hours for four doses followed by each society's recommended regimen to complete a total of 10 days.

Pregnancy is a hypercoagulable state and pregnant patients have up to a fivefold increased risk of thromboembolism compared to non-pregnant patients. 19, 20 Studies have suggested there may be a confounding increased risk of coagulopathy associated with COVID-19. 21-23 However, in critically ill patients therapeutic heparin was not shown to increase survival to hospital discharge or affect the number of days for respiratory organ support. 24 

Remdesivir is an inhibitor of the viral RNA-dependent RNA polymerase and it inhibits SARS-CoV-2 replication in vitro. 26 In an international, multicenter, double-blind, randomized, placebo-controlled trial of 1062 non-pregnant patients hospitalized with COVID-19 with evidence of lower respiratory tract infection, intravenous remdesivir (for 10 days or until hospital discharge or death) was superior to placebo in shortening the time to recovery. 27 Remdesivir was approved by the Food and Drug Administration (FDA) for use in adults and children (aged ≥12 years and weighing ≥40 kg) hospitalized with COVID-19. Safety data from the manufacture label of remdesivir states that there is insufficient data to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes when used in pregnant patients. 28 Data for the use of Remdesivir in pregnant women with COVID-19 are extremely limited. In a study by Burwick et al., 67 hospitalized pregnant patients (82% were ≥24 weeks gestation) with COVID-19 were treated on a compassionate use basis with remdesivir. 29 Among pregnant women, 93% of those on mechanical ventilation were extubated, 93% recovered, and 90% were discharged, and remdesivir was generally well tolerated. 29 Aside from this study, published data on outcomes and adverse events for remdesivir use in pregnant women with COVID-19 mostly come from smaller case series and case reports and are overall limited.

Tocilizumab is a monoclonal antibody against the interleukin-6 receptor, and it has shown to improve outcomes in patients with severe COVID-19 pneumonia in some studies. [30] [31] [32] [33] Tocilizumab is currently available under FDA emergency use authorization for the treatment of COVID-19. Tocilizumab crosses the placenta and data describing tocilizumab for use in pregnant patients with COVID-19 are scarce. Use for the treatment of COVID-19 in pregnancy is not J o u r n a l P r e -p r o o f currently recommended given limited data. Further study is necessary to confirm the benefit-risk profile of tocilizumab use among pregnant women.

The goal oxygen saturation for non-pregnant patients with COVID-19 is 92%. For pregnant patients, SMFM recommends a target of 95%. 18 Patients that do not require immediate intubation, high flow nasal canula is an appealing alternative. Pacheco at el. recommend initiation of 50-60 liters per minute (LPM) with 100% FIO2 and then subsequent weaning of FIO2 down to 40-50% followed by a decrease in flow by 5-10 LPM every 4-6 hours. 34 Non-invasive ventilation such as bilevel positive airway pressure (BIPAP) tends to be avoided in pregnancy because of an increased risk of aspiration due to decreased esophageal sphincter tone and increased abdominal pressure. 35

There is limited data regarding the management of mechanical ventilation for pregnant patients. In general, ventilatory strategies in the pregnant patient are similar to nonpregnant patients but with some key differences, especially in ARDS. In general, the PaCO2 should be aimed at a pregnancy-specific hypocapnia. 36 However, a severe respiratory alkalosis should be avoided as it leads to uterine vasoconstriction. 37 Hyperoxia in ARDS is avoided but for the pregnant patient the goal is an oxygen saturation of at least 95% and PaO2 of at least 70 mmHg to allow for adequate fetal oxygenation. 35 In the nonpregnant patient standard ARDS therapy also involves low tidal volume ventilation. If lung pathology constrains use of low tidal volume ventilation then permissive hypercapnia may be tolerated as it is not contraindicated in pregnancy; mild hypercapnia 50-60 mmHg is general acceptable. 36 However, if hypercapnia is greater than 60 mmHg there is a potential of fetal acidemia shifting the fetal oxyhemoglobin dissociation curve to the right. 36, 38 ARDSnet protocol recommends a goal plateau pressure of less than 30 cmH2O J o u r n a l P r e -p r o o f but given the reduction in chest wall compliance a higher plateau pressure greater than 30 cmH2O may be appropriate; especially because transpulmonary pressures may not be elevated. 39 Therefore, esophageal pressure monitoring may be helpful. 36

Critically ill patients on a ventilator need some form of analgesia and/or sedation. The 2018 Clinical Practice Guidelines for the Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU (PADIS) suggest using the analgesia-first approach to spare and/or minimize the use of both opioids and sedatives. 40 When sedation is needed, the guideline recommends using light sedation (vs deep sedation) in critically ill, mechanically ventilated patients using established assessment tools such as the Richmond Agitation and Sedation Scale. 40 There are some situations in which deeper sedation is targeted, such as patients with severe hypoxemia, severe ARDS, and patients who are receiving neuromuscular blocking agents.

There is limited evidence to guide decisions regarding sedation and analgesia in the critically ill pregnant patient. In general, commonly used agents for sedation and paralysis are safe in pregnancy. 41 Analgesic medications such as fentanyl, hydromorphone, and morphine are considered safe in pregnancy. 42 However, if used in pregnant patients close to the delivery time, neonatologists should be alerted as the neonate may develop signs of neonatal abstinence syndrome. 42 For sedation, the PADIS guideline suggests using either propofol or dexmedetomidine over benzodiazepines for sedation in critically ill mechanically ventilated adults. 40 There is no clear evidence that propofol causes congenital anomalies or adverse pregnancy outcomes. 42 Moreover, although Dexmedetomidine crosses the placenta there is no evidence that it is teratogenic. 42 

Paralytics are recommended for ventilated patients with moderate to severe ARDS to facilitate lung protective ventilation. 43 They can be used for persistent ventilator dyssynchrony, to enable proning, and to limit high plateau pressures. 43 When indicated cisatracurium is the preferred neuromuscular blocker and may be used during pregnancy. 42

The Prone Positioning in Severe Acute Respiratory Distress Syndrome (PROSEVA) trial has shown that in mechanically ventilated patients with ARDS, early application of prolonged prone-positioning sessions increases the rate of successful extubation and decreases mortality. 44 With regards to management of ARDS due to COVID-19, international treatment guidelines of critically ill adults with COVID-19 by the Surviving Sepsis Campaign panel suggest prone ventilation in moderate to severe ARDS for 12 to 16 hours. 43 However, data on pregnant patients are lacking as they were excluded from the PROSEVA trial. There are several case reports reporting successful prone ventilation in both non ventilated and ventilated pregnant patients with severe ARDS. [45] [46] [47] [48] [49] Proning pregnant patients is more challenging owing to the large gravid uterus but is feasible with padding using pillows and blankets above and below the gravid uterus. (Figure   2 ) This method offloads the uterus and avoids aortocaval compression. 36 

Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator that reduces the pulmonary artery pressure and increases arterial oxygenation in patients with severe ARDS. 50 While the antiviral property of iNO has been well described, 51 

Information on venous-venous extracorporeal membrane oxygenation (VV-ECMO) in pregnancy is limited. Nonetheless, pregnancy is not a contraindication. 18 patients with PaO2/FIO2 (P/F) ratios less than 80 for more than 6 hours, less than 50 for more than 3 hours, or a pH less than 7.25 with PaCO2 greater than 60 for more than 6 hours. 61 Cannulation site is affected by the stage of pregnancy. If the uterus fundus is at the level of the umbilics femoral cannulation may be difficult. 41 Therefore, the preferred cannulation method is a single dual lumen catheter in the right internal jugal vein; however, their smaller size may not match adequate flow needs due to the increased cardiac output of pregnancy. Once initiated, management of the ECMO circuit and weaning should follow ELSO protocols. 61 However, if the patient were to give birth on ECMO there is an increased risk of hemorrhage. Therefore, an ECMO strategy without anticoagulation could be considered as some reports have shown it to be safe. 62, 63 

Fetal monitoring should be viewed as yet another measure of maternal hemodynamics.

Fetal monitoring provides a non-invasive means of ensuring placental perfusion, as well as serving as a proxy for fetal oxygenation and acid-base status. 64 The key drivers to ensuring adequate placental perfusion are maternal hemodynamic stability, maternal oxygenation, volume status, and acid-base status. 41, 65, 66 There is little data to guide on the use of fetal monitoring in the critically ill pregnant patient; as such, a multidisciplinary team including MFM/high risk obstetrics, critical care, neonatology, and nursing should be utilized to determine the frequency, duration, and location of monitoring. Many variables are considered in making the decision to perform fetal monitoring; however, gestational age and maternal acuity should be atop the list. 67 The term "fetal viability" is often used when considering initiating fetal monitoring. At most centers, 22 weeks is the lowest threshold to consider a fetus viable, with most centers not recommending neonatal intervention until 24 weeks. The decision to initiate fetal monitoring J o u r n a l P r e -p r o o f should be based on balancing the family's expectation/desires for neonatal outcomes and the clinical situation. 68 As such, fetal monitoring should not be performed until a joint neonatology/MFM consultation has occurred. With advances in neonatal care and improved access to neonatal intensive care units, neonatal survival rates have progressively improved over time in the 22-24 week periviable period. 68 In the critically ill previable parturient, fetal heart auscultation at daily to weekly intervals is appropriate to confirm the pregnancy remains present; however, prior to viability, management plans should not deviate because of fetal status. Once the fetus is viable, fetal monitoring should be utilized to not only assure fetal health but also as yet another hemodynamic parameter to ensure placental perfusion. 69 The frequency of fetal monitoring needs to be individualized, and flexible, based on maternal acuity and decompensation. Recognizing practice vary by institution, a minimum of daily monitoring is recommended for the critically ill. Often, until maternal stability has been established or in the mechanically ventilated or ECMO patient, continuous monitoring is recommended. 67

The decision to proceed with delivery in the critically ill parturient needs to be balanced with 1) potential benefit toward maternal status and 2) risk of prematurity. In the setting of reassuring fetal monitoring and maternal stability, delivery is seldom recommended. In cases where ventilation cannot be optimized, consideration for delivery is appropriate to improve respiratory mechanics. 70 Decision making around delivery needs to include critical care medicine, neonatology, MFM, and obstetrics anesthesia. Delivery location should be prioritized to a labor and delivery suite, however, if delivery in the critical care setting is needed, multidisciplinary advanced planning is critical to ensure all resources are available for both the mother and neonate.

In our practice, delivery in the intensive care unit should be limited to perimortem cesarean delivery or where maternal / fetal status do not allow for any delay. Therefore, while in the ICU preparations should be made for imminent delivery in case of emergency. (Table-2 

As mentioned above, any parturient with a viable fetus should receive a course of glucocorticoids for fetal lung maturity if critical status presents prior to 34 weeks gestation. 71 Based on expert opinion from the current pandemic, the following should be considered in terms of timing of delivery. From the point of viability to 31w6d, delivery should be reserved for cases where maternal status continues to rapidly deteriorate or when fetus status is non-reassuring despite interventions. Beyond 32 weeks, delivery should be strongly considered in cases requiring mechanical ventilation or ECMO, after a course of glucocorticoids for fetal lung maturity. If maternal status deteriorates beyond 34 weeks, delivery is recommended. 67 It is important to note that mode of delivery (cesarean vs. induction of labor) should be determined by standard obstetrics principles if both maternal and fetus status allow. 66, 67, 70 Maternal cardiac arrest should prompt decision for urgent (less than 5 minute) perimortem cesarean delivery. A perimortem cesarean delivery should be performed wherever the arrest occurred; as such, preparing for delivery in the critical care setting is highly recommended. This delivery is performed to maximize maternal resuscitative efforts, most notably, improving cardiac return by decompressing the inferior vena cava of the gravid uterus allowing for more effective CPR. 72

Despite delivery occurring, pregnancy physiology continues for many weeks postpartum. 8 Irrespective of gestational age at time of delivery, there is a physiologic autotransfusion from the utero-placental unit into maternal circulation resulting in increased visceral perfusion and flow.

This auto transfusion results in increased pulmonary pressures and the resultant increased risk of pulmonary edema. 8, 73 In addition, an increase in catecholamines and fluid shifts during the postpartum period make the lungs particularly vulnerable to capillary leak. 73 The other significant consideration during the postpartum state is the increased risk of VTE. The increased thrombogenic state continues for up to 12 weeks postpartum, with the first 6 weeks carrying the highest risk of thromboembolism. 74 With the added risk associated with severe COVID-19, the postpartum critically ill patient should be considered high risk for thromboembolism and appropriate prophylaxis should be administered. As mentioned earlier, adjusted risk-based prophylactic dosing is recommended in critically ill patients, this recommendation still holds true for the postpartum patient. 66, 75 Lastly, lactation issues often arise in critically ill postpartum patients, and COVID-19 is no exception. The benefits of breastfeeding are well established, and every effort should be made to support this activity if it is consistent with the patient's wishes. In addition to the well-known benefits of breastfeeding, breast milk from COVID-19 postpartum patients has been shown to contain both anti-SARS-CoV-2 IgA and IgG, providing passive immunity to the vulnerable newborn. 76 Consultation with maternal-fetal medicine, lactation, pharmacy, and neonatology should occur to confirm medication compatibility with breastfeeding. Providing assistance with pumping or hand expression of milk by nursing staff, lactation, or family is critical to ensure adequate milk production and continue supply. 77

The pregnant patient is at increased risk for severe COVID-19 disease. Although there is limited data, management should focus on the early identification of the critically ill patient for triage to the ICU. Standard therapy includes medical management with steroids, and maintenance J o u r n a l P r e -p r o o f of an oxygenation saturation of at least 95%. The deteriorating patient requires special consideration with application of therapies such as proning, sedation/analgesia, paralysis, and VV-ECMO. Furthermore, particular attention to fetal monitoring, timing of delivery, and preparation for postpartum issues is essential. 

Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States

Adverse Pregnancy Outcomes, Maternal Complications, and Severe Illness Among US Delivery Hospitalizations With and Without a Coronavirus Disease 2019 (COVID-19) Diagnosis. Clin Infect Dis

Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study

Outcomes of Critically Ill Pregnant Women with COVID-19 in the United States

Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis

Risk Factors for Illness Severity Among Pregnant Women With Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 Infection-Surveillance for Emerging Threats to Mothers and Babies Network, 22 State, Local, and Territorial Health Departments

Physiologic changes during normal pregnancy and delivery

Pregnancy and COVID-19

Respiratory physiology in pregnancy

ISIDOG Recommendations Concerning COVID-19 and Pregnancy. Diagnostics (Basel)

Antenatal Corticosteroid Therapy for Fetal Maturation

Committee on Practice B-O. Practice Bulletin No. 171: Management of Preterm Labor

Antenatal corticosteroids for maturity of term or near term fetuses: systematic review and meta-analysis of randomized controlled trials

Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19)

Dexamethasone in Hospitalized Patients with Covid-19

COVID-19 Task Force. Management Considerations for Pregnant Patients With COVID-19

Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study

Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

Incidence of venous thromboembolism in hospitalized patients with COVID-19

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Remdesivir for the Treatment of Covid-19 -Final Report

Veklury (remdesivir) [package insert

Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19

Tocilizumab in Patients Hospitalized with Covid-19

Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19

Tocilizumab in COVID-19 therapy: who benefits, and how? -Authors' reply

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Early Acute Respiratory Support for Pregnant Patients With Coronavirus Disease 2019 (COVID-19) Infection

Respiratory Failure and Mechanical Ventilation in the Pregnant Patient

Prone Positioning for Pregnant Women With Hypoxemia Due to Coronavirus Disease 2019 (COVID-19)

Acute respiratory failure in pregnancy

Implications for the pregnant patient

Clinical review: Ventilatory strategies for obstetric, brain-injured and obese patients

Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU

Putting It All Together: Clinical Considerations in the Care of Critically Ill Obstetric Patients with COVID-19

Mechanical ventilation during pregnancy: sedation, analgesia, and paralysis

Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease

Prone positioning in severe acute respiratory distress syndrome

Prone positioning for ARDS following blunt chest trauma in late pregnancy

How safe is the prone position in acute respiratory distress syndrome at late pregnancy?

Severe acute respiratory distress syndrome in coronavirus disease 2019-infected pregnancy: obstetric and intensive care considerations

Prone positioning and high-flow oxygen improved respiratory function in a 25-week pregnant woman with COVID-19

Severe acute respiratory distress syndrome in pregnancy. Review of the literature and two cases report Med Crit

Inhaled nitric oxide for the adult respiratory distress syndrome

Nitric oxide and virus infection

S-nitrosylation of viral proteins: molecular bases for antiviral effect of nitric oxide. IUBMB Life

An antiviral mechanism of nitric oxide: inhibition of a viral protease

Nitric Oxide and Viral Infection: Recent Developments in Antiviral Therapies and Platforms

Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound

High Concentrations of Nitric Oxide Inhalation Therapy in Pregnant Patients With Severe Coronavirus Disease

Extracorporeal Life Support in Pregnancy: A Systematic Review

First successful treatment of a COVID-19 pregnant woman with severe ARDS by combining early mechanical ventilation and ECMO. Heart Lung

Survival of Pregnant Coronavirus Patient on Extracorporeal Membrane Oxygenation

Successful Treatment of Pregnant and Postpartum Women With Severe COVID-19 Associated Acute Respiratory Distress Syndrome With Extracorporeal Membrane Oxygenation. Asaio j

Extracorporeal Membrane Oxygenation for COVID-19: Updated 2021 Guidelines from the Extracorporeal Life Support Organization. Asaio j

Extracorporeal membrane oxygenation without systemic anticoagulation: a case-series in challenging conditions

Feasibility of Venovenous Extracorporeal Membrane Oxygenation Without Systemic Anticoagulation

Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles

Fetal oxygenation and maternal ventilation

General Care of the Pregnant Patient in the Intensive Care Unit. Semin Respir Crit Care Med

Timing of delivery with coronavirus disease 2019 pneumonia requiring intensive care unit admission

Periviable Birth

Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals

Management of Acute Respiratory Failure in Pregnancy. Semin Respir Crit Care Med

Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev

Trauma in pregnancy

Pregnancy with COVID-19: Management considerations for care of severe and critically ill cases

Risk of a thrombotic event after the 6-week postpartum period

Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Crit Care

Characterization of SARS-CoV-2 RNA, Antibodies, and Neutralizing Capacity in Milk Produced by Women with COVID-19. mBio